Tyrosine kinase inhibitorPhase 3 trialInvestigational
Mobocertinib
How it works
Blocks the EGFR and HER2 receptors on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR exon 20 insertion
Efficacy
In clinical trials, around 43% of EGFR exon 20 insertion patients achieved an objective response, with median progression-free survival of approximately 5.2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Insights into Resistance to Cancer Treatment in Lung Cancer Patients | Lung Cancer | observational | Mobocertinib achieved an objective response rate (ORR) of 59% and a disease control rate (DCR) of 82%, with a median progression-free survival (PFS) of 5.6 months (95% CI 3.5-9.3). | Source → |
| New Treatments for Lung Cancer with EGFR Exon 20 Mutations | Lung Cancer | review | — | Source → |
| New Cancer Treatment Shows Promise for Some Lung Cancer Patients | Lung Cancer | phase-1/2 | The confirmed objective response rate was 28%, median duration of response was 15.8 months, median progression-free survival was 7.3 months, and median overall survival was 20.2 months. | Source → |
| New Cancer Treatment Targets Specific Lung Cancer Mutation | Lung Cancer | lab-study | Mobocertinib inhibited growth of Ba/F3 cells expressing the ASV insertion with a half-maximal inhibitory concentration of 11 nM. | Source → |
| New Treatment Option for Lung Cancer Patients | Lung Cancer | phase-1/2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.